The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMicrosaic Regulatory News (MSYS)

Share Price Information for Microsaic (MSYS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.05
Bid: 1.00
Ask: 1.10
Change: 0.05 (4.76%)
Spread: 0.10 (10.00%)
Open: 1.05
High: 1.10
Low: 1.10
Prev. Close: 1.05
MSYS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI)

26 Aug 2020 09:04

RNS Number : 2063X
Nplus1 Singer Capital Markets Ltd
26 August 2020
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Nplus1 Singer Capital Markets Limited

 

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

MICROSAIC SYSTEMS PLC

 

(c) Name of the party to the offer with which exempt principal trader is connected:

MICROSAIC SYSTEMS PLC

(d) Date dealing undertaken:

25 August 2020

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

NO

 

If YES, specify which:

 

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

 

ORD 0.25P

 

 

Sale

 

550,000

 

0.5149p

 

0.5149p

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

Date of disclosure:

26 August 2020

Contact name:

Sarah-Rose Perry, Jennifer Bentick

Telephone number:

020 7496 3093

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FERGZGZRRVFGGZG
Date   Source Headline
6th May 201411:58 amRNSGRANT OF SHARE OPTIONS
30th Apr 20147:00 amRNSPreliminary Results
28th Apr 201412:33 pmRNSNotification of Major Interest in Shares
23rd Apr 20148:18 amRNSNotification of Major Interest in Shares
17th Apr 20149:19 amRNSHolding(s) in Company
15th Apr 20149:17 amRNSAppointment of Finance Director
14th Apr 20149:42 amRNSRe Agreement
11th Dec 20133:56 pmRNSHolding(s) in Company
21st Oct 20137:00 amRNSFormation of new Scientific Advisory Group
27th Sep 20137:00 amRNSInterim Results
1st Jul 20137:00 amRNSAppointment of Chairman
24th Jun 20137:00 amRNSIssue of Equity
4th Jun 20135:08 pmRNSHolding(s) in Company
4th Jun 20137:00 amRNSMicrosaic welcomes launch of the IsoleraT Dalton
31st May 201310:28 amRNSHolding(s) in Company
28th May 20132:44 pmRNSHolding(s) in Company
24th May 201311:23 amRNSResults of General Meeting
15th May 201311:23 amRNSResults of Annual General Meeting
7th May 20134:35 pmRNSDistribution of Circular of General Meeting
3rd May 20136:25 pmRNSConditional Placing to Raise up to £4.28 million
22nd Apr 20137:00 amRNSDistribution of Annual Report and Accounts
15th Apr 20137:00 amRNSPreliminary Results
10th Apr 20137:00 amRNSSigning of commercial agreement
15th Mar 20131:05 pmRNSHolding(s) in Company
14th Mar 20139:00 amRNSLaunch New Chip-based Mass Spectrometry Instrument
12th Dec 20129:36 amRNSGrant of Share Options
19th Oct 20124:45 pmRNSDirector/PDMR Shareholding
15th Oct 20122:26 pmRNSDirector/PDMR Shareholding
24th Sep 20127:00 amRNSAppointment of new CEO
24th Sep 20127:00 amRNSInterim Results
4th Sep 201210:00 amRNSAgreement
4th Jul 20129:46 amRNSGrant of Share Options
25th Jun 201210:29 amRNSMicrosaic Wins R&D100 Award
8th Jun 201210:53 amRNSHolding(s) in Company
7th Jun 20127:00 amRNSHolding(s) in Company
30th May 20123:40 pmRNSHolding(s) in Company
30th May 201211:36 amRNSAGM Results
29th May 201210:35 amRNSHolding(s) in Company
29th May 20127:00 amRNSPlacing
11th May 20129:18 amRNSHolding(s) in Company
9th May 20127:00 amRNSRe Agreement
30th Apr 20122:22 pmRNSDistribution of Annual Report and Accounts
25th Apr 20127:00 amRNSPreliminary Results
18th Apr 201210:07 amRNSMicrosaic Exhibits at Analytica 2012
22nd Feb 201211:21 amRNSHolding(s) in Company
12th Dec 20117:00 amRNSDirectorate Change
25th Nov 20119:04 amRNSExercise of Share Options
2nd Nov 20118:59 amRNSHolding(s) in Company
5th Oct 20119:33 amRNSHolding(s) in Company
3rd Oct 201111:35 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.